Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

April 23, 2010

First Antithrombotic Orally Disintegrating Tablets
Antiplatelet Agent "Pletaal^® OD Tablets" Launched on April 26

Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced that it launched "Pletaal^® OD Tablets 50 mg" and "Pletaal^® OD Tablets 100 mg" on April 26 as the first antithrombotic orally disintegrating tablets of antiplatelet agent "Pletaal^®" (non-proprietary name: cilostazol).

Latest Pharmaceutical Business related News Releases

17 APR 2023

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

30 JAN 2023

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan

10 JAN 2023

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Most Recent Releases

Otsuka Pharmaceutical Co., Ltd.

First Antithrombotic Orally Disintegrating Tablets Antiplatelet Agent "Pletaal® OD Tablets" Launched on April 26

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti® (brexpiprazole) in Japan

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

First Antithrombotic Orally Disintegrating Tablets
Antiplatelet Agent "Pletaal^® OD Tablets" Launched on April 26

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan